<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05024279</url>
  </required_header>
  <id_info>
    <org_study_id>21-0575</org_study_id>
    <nct_id>NCT05024279</nct_id>
  </id_info>
  <brief_title>Left Bundle Branch Area Pacing in Patients After TAVR</brief_title>
  <acronym>PLANET</acronym>
  <official_title>Pacing of the Left Bundle Branch Area NEcessitated After TAVR</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, randomized, single center clinical trial to compare the outcome of left bundle&#xD;
      branch area pacing versus right ventricular apical pacing in patients with higher degree&#xD;
      atrio-ventricular block and a normal left ventricular function after transcatheter aortic&#xD;
      valve replacement.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transcatheter aortic valve replacement (TAVR) is a well-established treatment of aortic valve&#xD;
      stenosis. Yet, requiry of permanent pacing due to new onset atrio-ventricular conduction&#xD;
      block remains a frequent complication. Standard right ventricular pacing (RVP) at high pacing&#xD;
      burden may lead to deterioration of left ventricular function. Left-Bundle-Area Pacing (LBBP)&#xD;
      is a new, innovative method of physiological ventricular stimulation resulting in narrow,&#xD;
      physiological QRS complexes.&#xD;
&#xD;
      In this prospective, randomized, single center clinica trial, patients are included after&#xD;
      TAVR and with normal left ventricular function who require pacing due to a higher degree&#xD;
      atriao-ventricular block with an anticipated high pacing burden. Patients will be randomized&#xD;
      to receive either left bundle branch area pacing (intervention) or right ventricular apical&#xD;
      pacing (control).&#xD;
&#xD;
      The results will confirm the feasibility of LBBP in patients following TAVR. Results will&#xD;
      further investigate the primary outcome of a clinically relevant QRS narrowing and a&#xD;
      combination of exploratory secondary endpoints including clinical outcomes, functional&#xD;
      status, laboratory biomarkers, and quality of life.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 6, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1:1 randomization</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>QRS duration</measure>
    <time_frame>3 months</time_frame>
    <description>QRS duration on 12-lead ECG, defined as earliest Q to latest S across all leads</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>QRS duration</measure>
    <time_frame>12 months</time_frame>
    <description>QRS duration on 12-lead ECG, defined as earliest Q to latest S across all leads</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QRS duration</measure>
    <time_frame>24 months</time_frame>
    <description>QRS duration on 12-lead ECG, defined as earliest Q to latest S across all leads</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death of any cause</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death of any cause</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death of any cause</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death of cardio-vascular cause</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death of cardio-vascular cause</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death of cardio-vascular cause</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-hospitalization due to heart failure</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-hospitalization due to heart failure</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-hospitalization due to heart failure</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricular ejection fraction</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricular ejection fraction</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricular ejection fraction</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in echocardiographic left ventricular enddiastolic diameter</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in echocardiographic left ventricular enddiastolic diameter</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in echocardiographic left ventricular enddiastolic diameter</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic assessment of degreee of atrio-ventricular valve insufficiency</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic assessment of degreee of atrio-ventricular valve insufficiency</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic assessment of degreee of atrio-ventricular valve insufficiency</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic assessment of right ventricular ejection fraction</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic assessment of right ventricular ejection fraction</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic assessment of right ventricular ejection fraction</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in New York heart failure classification status</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in New York heart failure classification status</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in New York heart failure classification status</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in laboratory biomarkers NT-proBNP</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in laboratory biomarkers NT-proBNP</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in laboratory biomarkers NT-proBNP</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in functional status by 6 minute walk</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in functional status by 6 minute walk</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in functional status by 6 minute walk</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EQ-5D quality of life</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EQ-5D quality of life</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EQ-5D quality of life</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of arrhythmias</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of arrhythmias</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of arrhythmias</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Pacemaker-associated complications</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Pacemaker-associated complications</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Pacemaker-associated complications</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>procedural implantation success</measure>
    <time_frame>basline</time_frame>
    <description>dichotomous yes / no</description>
  </other_outcome>
  <other_outcome>
    <measure>Implantation procedure duration</measure>
    <time_frame>baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Fluoroscopy duration</measure>
    <time_frame>baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Fluoroscopy dose</measure>
    <time_frame>baseline</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <condition>AV Block</condition>
  <condition>Pacing-Induced Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Intervention Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are randomized to receive left bundle branch are pacing due to higher degree AV block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients are randomized to receive standard right ventricular pacing due to higher degree AV block.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Left bundle branch area pacing</intervention_name>
    <description>Left bundle branch area pacing will be applied as established in the literature using commercially available equipment.&#xD;
In case of unsuccessful application of left bundle branch area pacing, cross-over to right ventricular pacing is allowed.</description>
    <arm_group_label>Intervention Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Right ventricular pacing</intervention_name>
    <description>Right ventricular pacing as the standard, established form of pacing will be applied in the control group. No cross-over to the intervention arm is anticipated.</description>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Successful TAVR implantation for classical (high flow high gradient), symptomatic&#xD;
             aortic valve stenosis&#xD;
&#xD;
          -  LVEF ≥50%&#xD;
&#xD;
          -  Guideline-based indication for pacing due to AV block III°, AV block II°, or&#xD;
             symptomatic bradycardic atrial fibrillation with an expecteed ventricular pacing&#xD;
             burden &gt;20%&#xD;
&#xD;
          -  Signed informeed conseent to study participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  LVEF &lt;50%&#xD;
&#xD;
          -  Expected pacing burden &lt;20%&#xD;
&#xD;
          -  Pre-existing implanted cardiac device&#xD;
&#xD;
          -  Participation in a concurring interventional trial&#xD;
&#xD;
          -  age &lt;18 years&#xD;
&#xD;
          -  Current preegnancy&#xD;
&#xD;
          -  life expectancy &lt;6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Moritz F Sinner, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>LMU Klinikum, Dept. of Cardiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephanie Fichtner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LMU Klinikum, Dept. of Cardiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Moritz F Sinner, MD, MPH</last_name>
    <phone>+49-89-4400</phone>
    <phone_ext>76159</phone_ext>
    <email>msinner@med.lmu.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephanie Fichtner, MD</last_name>
    <phone>+49-89-4400</phone>
    <phone_ext>73034</phone_ext>
    <email>stephanie.fichtner@med.uni-muenchen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>LMU Klinikum</name>
      <address>
        <city>Munich</city>
        <state>BY</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moritz F Sinner, MD, MPH</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 9, 2021</study_first_submitted>
  <study_first_submitted_qc>August 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2021</study_first_posted>
  <last_update_submitted>August 22, 2021</last_update_submitted>
  <last_update_submitted_qc>August 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>Moritz F. Sinner</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>left bundle branch area pacing</keyword>
  <keyword>av block</keyword>
  <keyword>right ventricular pacing</keyword>
  <keyword>aortic valve stenosis</keyword>
  <keyword>TAVR</keyword>
  <keyword>ECG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Atrioventricular Block</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

